BSE Live
Apr 13, 16:01Prev. Close
1000.65
Open Price
990.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 13, 16:00Prev. Close
1000.00
Open Price
993.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1001.15 (40)
| Balance Sheet of Strides Pharma Science (in Rs. Cr.) | Dec 09 | Dec 08 | Dec 07 | Dec 06 | Dec 05 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 40.22 | 40.05 | 35.00 | 34.95 | 34.95 | |
| Total Share Capital | 89.38 | 89.21 | 84.17 | 84.12 | 84.12 | |
| Reserves and Surplus | 820.95 | 289.73 | 160.80 | 278.47 | 253.62 | |
| Total Reserves and Surplus | 820.95 | 289.73 | 160.80 | 278.47 | 253.62 | |
| Total Shareholders Funds | 910.33 | 378.94 | 244.97 | 362.58 | 337.74 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 929.44 | 829.47 | 848.79 | 236.63 | 254.73 | |
| Deferred Tax Liabilities [Net] | 0.00 | 5.85 | 7.95 | 14.62 | 10.95 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 929.44 | 835.32 | 856.74 | 251.25 | 265.68 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 302.80 | 267.99 | 213.98 | 95.65 | 63.68 | |
| Trade Payables | 212.49 | 164.96 | 168.71 | 128.36 | 74.85 | |
| Other Current Liabilities | 8.14 | 33.64 | 63.80 | 5.52 | 10.47 | |
| Short Term Provisions | 169.55 | 70.92 | 29.27 | 31.55 | 25.83 | |
| Total Current Liabilities | 692.97 | 537.50 | 475.76 | 261.08 | 174.83 | |
| Total Capital And Liabilities | 2,550.35 | 1,753.56 | 1,596.45 | 910.35 | 781.82 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 201.87 | 152.21 | 157.54 | 152.34 | 116.93 | |
| Intangible Assets | 125.02 | 9.06 | 8.01 | 9.52 | 9.14 | |
| Capital Work-In-Progress | 11.21 | 145.41 | 50.46 | 37.98 | 44.68 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 338.11 | 306.67 | 216.01 | 199.85 | 170.75 | |
| Non-Current Investments | 1,518.04 | 939.58 | 590.32 | 298.29 | 233.45 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 1,856.15 | 1,246.25 | 806.34 | 498.14 | 404.20 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 95.50 | 86.97 | 72.21 | 63.83 | 50.28 | |
| Trade Receivables | 207.53 | 208.44 | 180.22 | 166.93 | 120.62 | |
| Cash And Cash Equivalents | 31.38 | 16.38 | 125.59 | 15.74 | 77.75 | |
| Short Term Loans And Advances | 359.79 | 195.51 | 166.25 | 154.27 | 91.96 | |
| OtherCurrentAssets | 0.00 | 0.00 | 245.85 | 11.45 | 37.02 | |
| Total Current Assets | 694.20 | 507.31 | 790.11 | 412.21 | 377.62 | |
| Total Assets | 2,550.35 | 1,753.56 | 1,596.45 | 910.35 | 781.82 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 163.25 | 212.57 | 192.61 | 309.54 | 141.94 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 159.93 | 111.72 | 72.82 | 80.19 | 59.16 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 12.91 | 43.26 | 26.57 | 25.65 | 18.69 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 24.07 | 21.91 | 27.20 | 14.66 | 21.37 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | 2.77 | -- | 1.90 | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 545.22 | 462.90 | 322.21 | 396.49 | 287.71 | |
| Other Earnings | 84.72 | 115.00 | 61.04 | 37.12 | 50.69 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 1,602.35 | 1,021.11 | 836.17 | 309.74 | 270.46 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
18.03.2026
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth